The JNK Inhibitor XG-102 Protects from Ischemic Damage with Delayed Intravenous Administration Also in the Presence of Recombinant Tissue Plasminogen Activator

Publisher： Karger

E-ISSN： 1421-9786|26|4|360-366

ISSN： 1015-9770

Source： Cerebrovascular Diseases, Vol.26, Iss.4, 2008-08, pp. : 360-366

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Very Early versus Delayed Rehabilitation for Acute Ischemic Stroke Patients with Intravenous Recombinant Tissue Plasminogen Activator: A Nationwide Retrospective Cohort Study

By  

Cerebrovascular Diseases, Vol. 42, Iss. 1-2, 2016-03 ,pp. : 41-48

Karger

Access to resources Recommend Favorite

Repeated Intravenous Treatment with Recombinant Tissue-Type Plasminogen Activator in Patients with Acute Ischemic Stroke

By  

European Neurology, Vol. 74, Iss. 3-4, 2015-09 ,pp. : 127-134

Karger

Access to resources Recommend Favorite

Vascular Aphasia Outcome after Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis for Ischemic Stroke

By  

European Neurology, Vol. 71, Iss. 5-6, 2014-02 ,pp. : 288-295

Karger

Access to resources Recommend Favorite

Effects of Uric Acid Levels on Outcome in Severe Ischemic Stroke Patients Treated with Intravenous Recombinant Tissue Plasminogen Activator

By  

European Neurology, Vol. 71, Iss. 3-4, 2013-12 ,pp. : 132-139

Karger

Access to resources Recommend Favorite

Intravenous Tissue Plasminogen Activator for an Ischemic Stroke with Occult Double Primary Cancer

By  

Case Reports in Neurology, Vol. 6, Iss. 3, 2014-10 ,pp. : 238-242

Karger

Access to resources Recommend Favorite